First Drug Shown to Delay Congestive Heart Failure in Dogs

Vetmedin is the first drug to go from an expanded conditional approval to fully approved

The U.S. Food and Drug Administration has fully approved a new use for Vetmedin (pimobendan) chewable tablets, making it the first drug officially recognized to delay the onset of congestive heart failure (CHF) in dogs diagnosed with Stage B2 preclinical myxomatous mitral valve disease (MMVD). Dogs in this stage show no outward symptoms but have a noticeable heart murmur and an enlarged heart.

This milestone is also significant because it marks the first time an animal drug indication has moved from expanded conditional approval to full approval. Vetmedin originally received conditional approval for this use in 2022 under the FDA’s expanded conditional approval pathway, which allows certain drugs to be marketed while additional effectiveness data are gathered.

The expanded pathway, introduced in 2018, was designed to encourage development of treatments for serious or unmet medical needs in major animal species when traditional studies would be especially complex or difficult.

Conditional approvals last one year and may be renewed annually for up to four years, provided the sponsor continues to make progress toward full approval.

After three renewals, Boehringer Ingelheim Animal Health USA submitted the required effectiveness data, leading to the FDA’s full approval of this new indication. Vetmedin is now fully approved to help veterinarians delay the progression of CHF in dogs with Stage B2 MMVD.

Read more

Read the FDA announcement here.